Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.

V. Dzutseva, D. Lioznov, I. Amosova,S. A. Sheetikov,K. V. Zornikova,Y. Serdyuk,G. A. Efimov, M. Tsyferov, M. Khmelevskii, A. Afansiev, N. Khomyakova, D. Zubkov,A. Tikhonov,T. Zhu,L. Barreto

PloS one(2023)

引用 0|浏览0
暂无评分
摘要
Trial registration: ClinicalTrials.gov: NCT04540419.
更多
查看译文
关键词
vaccine,double-blind,placebo-controlled,single-dose
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要